Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025341 | 0.84 | FDPS (0.33) | FDPSFPR2MEN1KMT2ANR3C1 | |
| SCHEMBL4077931 | 0.77 | MAPT (0.35) | FPR2ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL14254645 | 0.74 | KCNH2 (0.35) | FPR2KMT2AADORA3ADORA2AADORA2B | |
| SCHEMBL859290 | 0.72 | NR3C1 (0.33) | FPR2NR3C1ADORA3ADORA2AADORA2B | |
| SCHEMBL5654711 | 0.72 | ADORA3 (0.35) | FDPSFPR2MEN1KMT2ANR3C1 | |
| SCHEMBL13439283 | 0.72 | ADORA3 (0.33) | FPR2NR3C1ADORA3ADORA2AADORA2B | |
| SCHEMBL1106473 | 0.72 | ADORA2A (0.35) | FPR2NR3C1ADORA3ADORA2AADORA2B | |
| SCHEMBL18912116 | 0.71 | — | — | |
| SCHEMBL9444351 | 0.70 | TLR7 (0.39) | KMT2A | |
| SCHEMBL23043665 | 0.69 | ADORA3 (0.36) | FPR2NR3C1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | BRS3 223/4885FDPS 2178/4885FPR2 890/4885 |
| US-20190152941-A1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | TLR8, TLR1, TLR5 | BRS3 223/4885FDPS 2178/4885FPR2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.